{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:09:27Z","timestamp":1772327367777,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acuroe.2026.501917","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:15:47Z","timestamp":1767629747000},"page":"501917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Saouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guenouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"del Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00f3mez Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"AlShammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2026.501917_bib0005","unstructured":"Cancer Today (n.d.) [accessed 13 Jul]. Available from: http:\/\/gco.iarc.fr\/today\/home."},{"key":"10.1016\/j.acuroe.2026.501917_bib0010","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.03.025","article-title":"When and how to perform active surveillance for low-risk non-muscle-invasive bladder cancer","volume":"9","author":"Contieri","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2026.501917_bib0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.21037\/tau.2018.10.20","article-title":"Active surveillance for non-muscle invasive bladder cancer","volume":"8","author":"Gautier","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2026.501917_bib0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer\u2014a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): a Phase 2b, Open-Label, Single-Arm Trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jclinepi.2022.12.019","article-title":"Reporting according to the preferred reporting items for systematic reviews and meta-analyses for abstracts (PRISMA-A) depends on abstract length","volume":"154","author":"Helbach","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0040","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.acuroe.2026.501917_bib0045","first-page":"343","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.acuroe.2026.501917_bib0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","article-title":"Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group","volume":"29","author":"Bono","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000331727","article-title":"Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study","volume":"87","author":"Brausi","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.acuroe.2026.501917_bib0060","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","article-title":"Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer","volume":"155","author":"Colombo","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000052419","article-title":"Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion","volume":"39","author":"Colombo","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0070","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0075","first-page":"324","article-title":"Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study","volume":"73","author":"Decaestecker","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.acuroe.2026.501917_bib0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(01)66552-2","article-title":"Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer","volume":"155","author":"Maffezzini","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0090","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.1994.tb16585.x","article-title":"Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin","volume":"74","author":"Popert","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, Phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2026.501917_bib0115","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-5347(17)54246-9","article-title":"Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients","volume":"127","author":"Prout","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.acuroe.2026.501917_bib0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"European Organization for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0130","first-page":"199","article-title":"Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours","volume":"29","author":"van der Meijden","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0135","doi-asserted-by":"crossref","first-page":"165.e19-23","DOI":"10.1016\/j.urolonc.2015.11.005","article-title":"Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer","volume":"34","author":"Hern\u00e1ndez","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience","volume":"5","author":"Contieri","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.acuro.2022.01.002","article-title":"Surveillance and office management of low-grade Ta bladder tumors","volume":"46","author":"Lokeshwar","year":"2022","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2026.501917_bib0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.juro.2007.08.171","article-title":"Conservative management of low risk superficial bladder tumors","volume":"179","author":"Pruthi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2724-6051.21.04613-9","article-title":"Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?","volume":"74","author":"Paciotti","year":"2022","journal-title":"Minerva Urol Nephrol"},{"issue":"2 Pt 1","key":"10.1016\/j.acuroe.2026.501917_bib0165","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0170","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2026.501917_bib0175","doi-asserted-by":"crossref","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, Dominguez Escrig JL, Liedberg F, Mariappan P, et al. EAU Guidelines on-muscle-invasive Bladder Cancer (TaT1 and CIS) 2024;86:531-49.","DOI":"10.1016\/j.eururo.2024.07.027"},{"key":"10.1016\/j.acuroe.2026.501917_bib0180","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/curroncol31040163","article-title":"Active surveillance in non-muscle invasive bladder cancer, the potential role of biomarkers: a systematic review","volume":"31","author":"Parrao","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bju.13536","article-title":"Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project","volume":"118","author":"Hurle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2026.501917_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2017.02.874","article-title":"Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project","author":"Hurle","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501917_bib0195","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2018.05.006","article-title":"Pathological outcomes for patients who failed to remain under active surveillance for low-risk non-muscle-invasive bladder cancer: update and results from the bladder cancer Italian Active Surveillance Project","volume":"1","author":"Hurle","year":"2018","journal-title":"Eur Urol Oncol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:38:45Z","timestamp":1772325525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578626000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2173578626000041"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.501917","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.501917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501917","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501917"}}